| الوصف: |
// Lisha Ying 1, 2, * , Fanrong Zhang 2, * , Xiaodan Pan 3 , Kaiyan Chen 2 , Nan Zhang 2 , Jiaoyue Jin 2 , Junzhou Wu 2 , Jianguo Feng 2 , Herbert Yu 4 , Hongchuan Jin 1 , Dan Su 2 1 Laboratory of Cancer Biology, Provincial Key Lab of Biotherapy in Zhejiang, Sir Runrun Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China 2 Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China 3 Tissue Bank of Zhejiang Cancer Hospital, Hangzhou, China 4 Cancer Epidemiology Program, University of Hawaii Cancer Center, Hawaii, USA * These authors have contributed equally to this work Correspondence to: Dan Su, email: sudan@zjcc.org.cn Hongchuan Jin, email: jinhc@zju.edu.cn Keywords: complement component 7, tumor progression, prognosis, ovarian cancer, non-small cell lung cancer Received: September 02, 2016 Accepted: October 29, 2016 Published: November 11, 2016 ABSTRACT Our previous study found copy number variation of chromosome fragment 5p13.1-13.3 might involve in the progression of ovarian cancer. In the current study, the alteration was validated and complement component 7 (C7), located on 5p13.1, was identified. To further explore the clinical value of C7 in tumors, 156 malignant, 22 borderline, 33 benign and 24 normal ovarian tissues, as well as 173 non-small cell lung cancer (NSCLC) tissues along with corresponding adjacent and normal tissues from the tissue bank of Zhejiang Cancer Hospital were collected. The expression of C7 was analyzed using reverse transcriptase quantitative polymerase chain reaction. As a result, the C7 expression displayed a gradual downward trend in normal, benign, borderline and malignant ovarian tissues, and the decreased expression of C7 was correlative to poor differentiation in patients with ovarian cancer. Interestingly, a similar change of expression of C7 was found in normal, adjacent and malignant tissues in patients with NSCLC, and low expression of C7 was associated with worse grade and advanced clinical stage. Both results from this cohort and the public database indicated that NSCLC patients with low expression of C7 had a worse outcome. Furthermore, multivariate cox regression analysis showed NSCLC patients with low C7 had a 3.09 or 5.65-fold higher risk for relapse or death than those with high C7 respectively, suggesting C7 was an independent prognostic predictor for prognoses of patients with NSCLC. Additionally, overexpression of C7 inhibited colony formation of NSCLC cells, which hints C7 might be a potential tumor suppressor. |
